169 related articles for article (PubMed ID: 23721399)
1. Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy.
Zhu Y; Li Q; Gao J; He Z; Sun R; Shen G; Zhang H; Xia W; Xu J
Breast J; 2013; 19(4):382-7. PubMed ID: 23721399
[TBL] [Abstract][Full Text] [Related]
2. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
López-Bonet E; Alonso-Ruano M; Barraza G; Vazquez-Martin A; Bernadó L; Menendez JA
Oncol Rep; 2008 Dec; 20(6):1369-74. PubMed ID: 19020716
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature.
Rovera F; Lavazza M; La Rosa S; Fachinetti A; Chiappa C; Marelli M; Sessa F; Giardina G; Gueli R; Dionigi G; Rausei S; Boni L; Dionigi R
Int J Surg; 2013; 11 Suppl 1():S79-83. PubMed ID: 24380560
[TBL] [Abstract][Full Text] [Related]
4. Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review.
Alkaied H; Harris K; Brenner A; Awasum M; Varma S
Clin Breast Cancer; 2012 Jun; 12(3):226-30. PubMed ID: 22424945
[TBL] [Abstract][Full Text] [Related]
5. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
Iyoda A; Hiroshima K; Moriya Y; Iwadate Y; Takiguchi Y; Uno T; Nakatani Y; Yoshino I
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):446-53. PubMed ID: 19619794
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
[TBL] [Abstract][Full Text] [Related]
9. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
10. Primary large cell neuroendocrine carcinoma of the breast, a case report with an unusual clinical course.
Janosky M; Bian J; Dhage S; Levine J; Silverman J; Jors K; Moy L; Cangiarella J; Muggia F; Adams S
Breast J; 2015; 21(3):303-7. PubMed ID: 25823996
[TBL] [Abstract][Full Text] [Related]
11. Solid neuroendocrine carcinoma of the breast.
Abbasi NZ; Zahur Z; Sheikh AS; Khan AA; Ali F; Memon KH; Moizuddin SS; Loya A; Barkat N
J Coll Physicians Surg Pak; 2013 Nov; 23(10):820-2. PubMed ID: 24169396
[TBL] [Abstract][Full Text] [Related]
12. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy.
Tanaka Y; Ogawa H; Uchino K; Ohbayashi C; Maniwa Y; Nishio W; Nakao A; Yoshimura M
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):839-46. PubMed ID: 22498090
[TBL] [Abstract][Full Text] [Related]
14. A case of cytokeratin 20-positive large-cell neuroendocrine carcinoma of the breast.
Okoshi K; Saiga T; Hisamori S; Iwaisako K; Kobayashi H; Ogawa H
Breast Cancer; 2012 Oct; 19(4):360-4. PubMed ID: 19669861
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
16. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
17. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
18. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Khakpour N; Soliman H; Catherine Lee M
Breast J; 2012; 18(6):569-74. PubMed ID: 23034096
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report.
Zhang Y; Liu C; Zheng C; Ren Q; Wang Q; Gao X; He Y; Wu J; Chen G; Li X; Ma Z
Medicine (Baltimore); 2020 Oct; 99(43):e22652. PubMed ID: 33120755
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
Arce-Salinas C; Lara-Medina FU; Alvarado-Miranda A; Castañeda-Soto N; Bargalló-Rocha E; Ramírez-Ugalde MT; Pérez-Sánchez V; Rivera L; Gambo-Vignole C; Santamaría-Galicia J; Nieves-Casas RI; Morán-Muñoz H; Mohar-Betancourt A
Rev Invest Clin; 2012; 64(1):9-16. PubMed ID: 22690524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
